A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Stopped Due to lack of expected efficacy shown at the time of the interim analysis
Conditions
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Cutaneous Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Castration-resistant Prostate Cancer
- Ovarian Cancer
Interventions
- DRUG: Nanrilkefusp Alfa
- DRUG: Pembrolizumab
Sponsor
SOTIO Biotech AG
Collaborators